Clinical-stage biotechnology company REGENXBIO Inc. (Nasdaq:RGNX) announced on Monday positive results from its Phase II fellow eye sub-study evaluating ABBV-RGX-314 for patients with bilateral wet age-related macular degeneration (wet AMD).

Data, presented by Arshad Khanani, M.D., M.A., FASRS, at the American Academy of Ophthalmology meeting, show ABBV-RGX-314's potential to treat both eyes in patients with bilateral disease. This marks the first gene therapy sub-study for wet AMD in fellow eyes, bolstering the growing body of evidence supporting ABBV-RGX-314's impact on the treatment landscape.

With the largest cohort of treated patients and the longest-term follow-up data for a gene therapy in wet AMD, REGENXBIO, alongside AbbVie, is well-positioned to lead in gene therapy innovation.

Dr. Khanani said that patients with bilateral wet AMD often face a high treatment burden and suboptimal real-world vision outcomes with current therapies. The fellow eye dosing data represents a significant milestone for gene therapy in retinal diseases. Long-term results, showing durable effects up to four years, highlight ABBV-RGX-314 as a potential one-time treatment option for these patients.